ClinicalTrials.gov
ClinicalTrials.gov Menu

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02509195
Recruitment Status : Completed
First Posted : July 27, 2015
Last Update Posted : February 28, 2018
Sponsor:
Collaborator:
ViiV Healthcare
Information provided by (Responsible Party):
St Stephens Aids Trust

Brief Summary:

The purpose of this study is to identify the effects that ageing may have on the drug levels, the safety and the efficacy of Dolutegravir.

These effects will be measured in people who are aged 60 or over and taking antiretroviral therapy for HIV infection.

Dolutegravir is a newly licenced anti HIV medication, which belongs to a class of drugs called Integrase Inhibitors. It is taken with two other wellknown agents, Abacavir and Lamivudine, as part of a one tablet once a day regimen, called Triumeq. There is little data available on Dolutegravir in the context of older age. The HIV population is ageing and the investigators know that older age can significantly change the effects and side effects of medications, including that of antiretrovirals.

The investigators aim to investigate the treatment outcomes in older people taking Dolutegravir including the tolerability, efficacy and safety of the drug.

The study will also assess the quality of life (wellbeing of individuals) and cognition (mental abilities) of people aged 60 or over, taking Dolutegravir. The results from this study may inform treatment choices and monitoring in this population in the future.

The duration of involvement in the study will be 6 months with an additional screening visit and a checkup visit 10 days after end of study visit.


Condition or disease Intervention/treatment Phase
HIV Drug: Triumeq Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study to Investigate the Safety and Efficacy of Abacavir/Lamivudine/Dolutegravir and the Pharmacokinetic Profile of Dolutegravir in HIV-infected Patients of 60 Years of Age and Older
Actual Study Start Date : August 4, 2015
Actual Primary Completion Date : February 13, 2017
Actual Study Completion Date : July 24, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Switch to Triumeq
HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
Drug: Triumeq
Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
Other Name: abacavir/lamivudine/dolutegravir




Primary Outcome Measures :
  1. Steady state plasma concentrations of dolutegravir when administered to HIV-infected individuals over the age of 60/65 years. [ Time Frame: Day 28 ]

Secondary Outcome Measures :
  1. Safety on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater - measured by Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. [ Time Frame: Up to day 190 ]
  2. Tolerability on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater- measured by Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. [ Time Frame: Up to day 190 ]
  3. Maintenance of HIV viral load control on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater. [ Time Frame: Up to day 190 ]
  4. Quality of life on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater.- Measured by questionnaire [ Time Frame: Up to day 190 ]
  5. Sleep Quality on abacavir/lamivudine/dolutegravir once daily in HIV-infected subjects of 60 years or greater - Measured by questionnaire [ Time Frame: Up to day 190 ]
  6. Measurement of the metabolic profile in patients over the age of 60 with HIV infection who switch antiretroviral regime (metabonomics) [ Time Frame: Up to day 180 ]
  7. Cerebral function via cognitive testing before and after a switch in antiretroviral therapy to a dolutegravir containing regimen [ Time Frame: Up to day 180 ]
  8. Relationship between genetic polymorphisms and exposure to dolutegravir as measured by Peak plasma concentration (Cmax) [ Time Frame: Day 1 ]
    The results of genetic polymorphisms testing indicating the presence or absence of certain polymorphisms coding for enzymes and transporters responsible for the metabolism of dolutegravir will be correlated with the PK parameter Peak plasma concentration (Cmax). This, for instance, can tell us if the presence of certain alleles makes an individual more likely to metabolise or clear dolutegravir faster or slower.

  9. Relationship between genetic polymorphisms and exposure to dolutegravir as measured by trough concentration (Ctrough) [ Time Frame: Day 1 ]
    The results of genetic polymorphisms testing indicating the presence or absence of certain polymorphisms coding for enzymes and transporters responsible for the metabolism of dolutegravir will be correlated with the PK parameter trough concentration (Ctrough). This, for instance, can tell us if the presence of certain alleles makes an individual more likely to metabolise or clear dolutegravir faster or slower.

  10. Relationship between genetic polymorphisms and exposure to dolutegravir as measured by Area under the plasma concentration versus time curve (AUC) [ Time Frame: Day 1 ]
    The results of genetic polymorphisms testing indicating the presence or absence of certain polymorphisms coding for enzymes and transporters responsible for the metabolism of dolutegravir will be correlated with the PK parameter Area under the plasma concentration versus time curve (AUC). This, for instance, can tell us if the presence of certain alleles makes an individual more likely to metabolise or clear dolutegravir faster or slower.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HIV-1 infected males or females
  2. Has voluntarily signed informed consent after having enough time to consider the study information.
  3. Is willing to comply with the protocol requirements
  4. Documentation that the subject is negative for the HLA-B*5701 allele, either on historical sample or if none available, at screening.
  5. Aged 60 years and over (approximately 70% of the study participants will be ≥65 year of age), willing to switch therapy as per study protocol with no previous use of dolutegravir
  6. Plasma HIV RNA < 50 copies/mL at screening (single re-test allowed) and on at least one other occasion over the last 6-8 months
  7. Has a CD4 cell count at screening >50 cells/mm3
  8. Currently receiving a stable antiretroviral regimen with no antiretroviral drug switches for at least 3 months prior to planned study baseline.
  9. No previous clinically-significant resistance documented on HIV-1 genotypic resistance to NRTIs and INIs
  10. Subjects in good health upon medical history, physical exam, and laboratory testing and with a clinically managed cardiovascular disease in the opinion of the Investigator
  11. Body mass over 40 kg and body mass index (BMI) above or equal to 18 and below 35
  12. Male subjects who are heterosexually active must be willing to use appropriate and consistent dual method contraception during heterosexual intercourse with women of child bearing potential, from screening through to one month post completion of the study. The following combined contraceptive methods are acceptable (please see appendix 3):

    1. Double barrier method:

      • Male Condom combined with a Female Diaphragm with or without a vaginal spermicide* (foam, gel, film, cream, or suppository)
      • Male Condom combined with a Cervical cap** (with spermicide)
    2. Male Condom + one of the following:

      • Combined Oral Contraceptive Pill
      • Combined Contraceptive Patch
      • Combined Vaginal Ring
      • The Progesterone Only Pill
      • Intra-uterine Device (Copper IUD or the IUS)
      • Injectable progestogen (Depo provera®)
      • The progestogen-only Subdermal Implant

Footnotes:

  1. *Cervical caps in women who have given birth is less effective than other methods of contraception.
  2. **Spermicide should be used with caution as this can potentially increase the rate of HIV-1 transmission.
  3. ***It is advised not to use a male and female condom together due to risk of breakage or damage caused by latex friction.

If a female partner has had a total hysterectomy (surgical removal of the womb) or bilateral tubal ligation/clip (surgical sterilization), then she cannot get pregnant and the above section does not apply. If the male subject has had a vasectomy at least 1 month prior to starting the study, he does not need to use any other birth control.

Exclusion Criteria:

  1. History or presence of allergy to the study drugs or their components
  2. Infected with HIV-2
  3. Using any concomitant therapy disallowed as per SPC for the study drugs. The SPC of a drug is updated regularly. The most recent version can be found on http://www.medicines.org.uk/emc/
  4. Known acute viral hepatitis including, but not limited to, A, B, or C
  5. Known chronic hepatitis B and/or C
  6. Tests newly positive for active Hepatitis B (HBsAg positive), or active Hepatitis C (PCR positive) at screening visit
  7. Any investigational drug within 30 days prior to the trial drug administration
  8. Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥1.5xULN (with >35% direct bilirubin)
  9. Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification
  10. Moderate or severe renal impairment (creatinine clearance < 50ml/min)
  11. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
  12. Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with the assessments or completion of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02509195


Locations
United Kingdom
St Stephen's Centre, Chelsea & Westminster Hospital
London, United Kingdom, SW10 9NH
Sponsors and Collaborators
St Stephens Aids Trust
ViiV Healthcare
Investigators
Principal Investigator: Marta Boffito St Stephen's AIDS Trust

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: St Stephens Aids Trust
ClinicalTrials.gov Identifier: NCT02509195     History of Changes
Other Study ID Numbers: SSAT064
2014-004970-40 ( EudraCT Number )
First Posted: July 27, 2015    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018

Additional relevant MeSH terms:
Lamivudine
Abacavir
Dideoxynucleosides
Dolutegravir
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Antimetabolites